^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
InnoSIGN

i
Other names: InnoSIGN | INNOSIGN | Inno-SIGN Innosign
Related tests:
Evidence

News

1m
Collaboration with NYU Langone Health in breast cancer (InnoSIGN Press Release)
"NYU Langone Health published their study in Journal of Clinical Pathology showing that increased PI3K pathway activity, independent of PIK3CA mutations, may play a role in the recurrence of early-stage breast cancer with low and intermediate 21-gene RS."
Clinical data
|
Oncotype DX Breast Recurrence Score®Test
4ms
Identifying mutation-independent signaling pathway activation in molecular subtypes of triple negative breast cancers (InnoSIGN Press Release)
"The InnoSIGN team...during the San Antonio Breast Cancer Symposium (SABCS), from Wednesday December 6 to Friday 8 December, 2023...An abstract by NYU-Langone and two abstracts by InnoSIGN have been selected for poster presentation in the scientific program."
Clinical data
|
OncoSignal™
5ms
Meet InnoSIGN at Association for Molecular Pathology (AMP) 2023 (InnoSIGN Press Release)
"The InnoSIGN team is excited to meet you at this year’s AMP Annual Meeting & Expo in Salt Lake City, US, from Tuesday November 14 to Saturday 18 November, 2023...Applications of OncoSIGNal pathway profiling platform in breast cancer and bladder cancer will be presented at the InnoSIGN corporate workshop..."
Clinical data
|
OncoSignal™
5ms
InnoSIGN starts offering OncoSIGNal pathway profiling services for clinical use in the US (InnoSIGN Press Release)
"...InnoSIGN Inc...announces the offering of its OncoSIGNal pathway profiling platform for clinical use as a Laboratory Developed Test (LDT) through InnoSIGN’s high-complexity CLIA laboratory...OncoSIGNal is the first platform identifying the tumor-driving cell signaling pathways in tumor tissue."
Clinical
|
OncoSignal™
7ms
InnoSIGN receives grant of almost €700K for ovarian cancer multicenter trial (InnoSIGN Press Release)
"InnoSIGN B.V. and the Catharina Hospital Eindhoven receive a grant of almost € 700 000 by the European subsidy program OPZuid for the 'STA-OP' multicenter prospective clinical trial, starting April 2023 (for 3 years). The objective of this trial is to identify new personalized targeted therapies based on 'Signal Transduction pathway Activity for recurrent Ovarian cancer Patients'...In this clinical trial InnoSIGN’s proprietary OncoSIGNal technology will be used to identify the tumor driving cell signaling pathways in the patient tumor tissue to direct patients to personalized therapies with targeted drugs that inhibit the activity of these pathways."
Grant
|
OncoSignal™
9ms
Institut Gustave Roussy: OncoSIGNal predicts resistance to AR targeted drugs in mCR prostate cancer (InnoSIGN Press Release)
"...Institut Gustave Roussy, published in Clinical Cancer Research their findings using OncoSIGNal for prostate cancer...'Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors'...It is shown that Low AR activity, activation of stemness programs, and Hedgehog pathway were associated with primary androgen receptor axis inhibitors’ resistance, whereas most acquired resistance was associated with subclonal evolution, AR-related events, and neuroendocrine differentiation."
Clinical data
|
OncoSignal™
12ms
Racial differences in estrogen receptor signaling pathway activity in breast cancer patient (InnoSIGN Press Release)
"Joy Zhou Done from Johns Hopkins Hospital will present her findings on racial differences in ER staining positive breast cancer during the American Society of Breast Surgeons 24th Annual Meeting in Boston, US...By using OncoSIGNal there were measurable differences in ER pathway activity between White and Black patients prior to hormonal treatment, although all tumors were ER+ by immunohistochemistry."
Clinical data
|
OncoSignal™
12ms
Presentation of OncoSIGNal at the AACR (InnoSIGN Press Release)
"InnoSIGN presents the use of OncoSIGNal in triple breast cancer patients to identify new targeted treatment options."
Retrospective data
|
OncoSignal™